Featured on Jan 9th, 2023

BIO89-100

Treatment for Liver & Metabolic Disorders

CHECK IT OUT

A novel long-acting glycopegylated fibroblast growth factor 21 analogue; the BIO89-100 Treatment for Liver & Metabolic Disorders could become a therapy for NASH (nonalcoholic steatohepatitis) given its ability to address the key liver pathologies (steatosis & fibrosis) & underlying metabolic dysregulation in NASH patients.

Hunted by @nigelmarkdias

$0.00·0 votes· comments